Alumis' Lupus Trial Misses Goals Overall, but High-Interferon Subgroup Responds
- Alumis' Phase 2b LUMUS trial of envudeucitinib, an oral TYK2 inhibitor, missed its primary and key secondary endpoints in the overall lupus (SLE) patient population.
- A prespecified subgroup with a high interferon gene signature (IFNGS-high) — the patient profile most reliant on the Type I interferon pathway that TYK2 inhibition targets — showed a clear, placebo-separated response on the same endpoints.
- These IFNGS-high patients were underrepresented in the overall study population, which diluted the topline result.
- The drug was well tolerated, with no new safety signals.
- Alumis plans to redesign its Phase 3 program around IFNGS-high patients, engage the FDA before year-end, and separately still intends to file for U.S. psoriasis approval by the end of 2026.
A miss with an asterisk, not a pivot. IFNGS-high response is biologically coherent — interferon signature is literally TYK2's mechanism — so this isn't pure spin like some post-hoc subgroup rescues. But shrinking Phase 3 to biomarker-enriched patients trades a bigger addressable market for a better shot at significance; that's the right call scientifically, wrong one commercially unless a companion diagnostic scales cleanly. Versus BMS's already-approved Sotyktu, Alumis needed a clean topline to differentiate TYK2 in autoimmune beyond psoriasis — it didn't get one. Expect the Street to stay skeptical until FDA blesses the enrichment strategy; a >50% drop doesn't reverse on a CEO's confidence alone. Psoriasis filing is now doing the heavy lifting for the story — good, since it's biomarker-agnostic — but lupus was supposed to be the platform proof point, and that thesis just got smaller.
Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward' ↗